Results: The frequency of heterozygote rs33996649GA genotype was higher in pSS patients than HS [OR=3.143 (1–10.234), p=0.046], and also, rs33996649GA genotype was associated with high SSDAI score (p<0.01). The pSS patients showed 44-fold more mRNA expression in comparison with HS (p=0.002), and mRNA expression correlates with SSDAI (r²=0.512, p=0.006).

Conclusion: The rs33996649G-A genetic variant of the PTPPN22 gene is associated with increased development risk of pSS in the western Mexican population. The expression mRNA correlates with disease activity in pSS.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.2173

AB0017

CONSTANT LINK WITH TUMOR NECROSIS FACTOR IL1B T-31C IS ASSOCIATED WITH ANAMNESIS OF BIOLOGICAL DRUGS TREATMENT IN RHEUMATOID ARTHRITIS

V. Omelchenko1, E. Letyagina1, Y. Kurochkina1, A. Akimova1, A. Shevchenko1, M. Korolev2, RICEL – Branch of IC&G SB RAS, Novosibirsk, Russian Federation

Background: Rheumatoid arthritis (RA) is chronic progressive joint disease with erosions formation. Timely and effectiveness treatment is important due to quickly structural damage and progressive losing of active motion. Synthetic DMARDs didn't have a sufficient effect. Using biological drugs seemed like a panacea, but according to investigations at least 30-40% RA-patients lost treatment efficiency. Biological drugs act through immune cascade, that's why mutation in regulatory gene is associated with biological drugs prescribing.

Methods: One hundred two Caucasian RA-patients (age – 56 yrs [45; 61]; DAS28 4.7 [3.8; 5.9]) were enrolled in our study. All of them had American College of Rheumatology (ACR)-defined RA (1987 classification criteria) and gave written informed consent. Single nucleotide polymorphisms IL1B T-31C (rs1143627), IL4 C-590T (rs2243250), IL10 A-1082G (rs1800872), IL10 C-592A (rs1800896) were amplified using PCR. Good-quality amplicons were sequenced (Sanger method).

Results: The SNP is a promoter polymorphism that could affect the auto-inflammatory response and the therapy responsiveness, as suggested by our preliminary data of pharmacogenomics. Analyses of a larger cohort of patients are needed to confirm the study findings and to explain the SNP role as outcome predictor.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4119

AB0019

GENETIC POLYMORPHISM OF THE INFLAMMATORY MARKER SAA1 RS12218 (-13 T/C) IS ASSOCIATED WITH AN ATTITUDE TO CLINICAL PHENOTYPES OF JUVENILE IDIOPATHIC ARTHRITIS

E. Fedorov1, S. Salugina3, M. Krylov2, I. Guseva3, E. Samarkina3, 1VA. Nasonova Research Institute of Rheumatology, Pediatric, Moscow, Russian Federation; 2VA. Nasonova Research Institute of Rheumatology, Pediatric, Moscow, Russian Federation; 3VA. Nasonova Research Institute of Rheumatology, Immunology and Molecular Biology of Rheumatic Diseases, Moscow, Russian Federation

Background: Juvenile idiopathic arthritis (JIA) is one of the most widely spread immune-inflammatory diseases of an unknown etiology, the leading manifestation of which is chronic joint inflammation, occurring in children under the age of 16. The disease is a complex of chronic arthropathies with various phenotypic manifestations.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.2295

AB0018

TNFA RS1800629 POLYMORPHISM: WHAT ABOUT ITS ASSOCIATION WITH CLINICAL MANIFESTATIONS AND ANTI-TNF-A THERAPY? DATA FROM A SERIES OF ITALIAN PATIENTS WITH BEHÇET SYNDROME

M. C. Padula1,2, P. Lecceesa1, N. Lascaro1, G. G. Sorrento1, R. P. Radioco2, A. R. Limongi2, T. Carbones3, A. Padulab1, G. Martellio3, S. D'Angelo1, 1Rheumatology Institute of Lucania (IReL), San Carlo Hospital of Potenza, Potenza, Italy; 2University of Basilicata, Potenza, Italy

Background: Tumor Necrosis Factor-alpha (TNF-α) is a pleiotropic cytokine with a critical role in the pathogenesis of Behçet syndrome (BS). Anti-TNF-α therapy is useful for patients with refractory, severe BS, in particular for ocular, central nervous system, and gastrointestinal manifestations. However, although biological treatment with anti-TNF-α agents is effective in BS, not all patients are definite responders. Non-responders patterns could be due to: alternative non-TNFα related pathway of inflammation; anti-drug antibodies presence or development; polymorphic alleles of TNFα genes. TNFα rs1800629 (-308G/A) is a drug-response single nucleotide polymorphism (SNP) located within the gene promoter. Poor and conflicting data are currently available about the association of this polymorphism and clinical manifestations of BS, as well as about the responsiveness to the TNFα blockers in BS patients [1-3].

Objectives: Aims of this study were to investigate in a cohort of Italian patients with BS the frequency of rs1800629 genotypes and its association with clinical features and anti-TNFα therapy response.

Methods: Consecutive patients with BS were recruited. Patients demographic and clinical data were collected by medical records and analyzed. Home-made specific primer pairs were used for rs1800629 coverage. gDNA was isolated and amplified using PCR. Good-quality amplicons were sequenced (Sanger method).

Results: 130 BS patients (64M-66F; mean age: 45.8±12.3 years) were included in the study. Patients predominant lesions were oral aphthosis (100%), eye involvement (86.2%), skin lesions (72.3%) and genital ulcers (57.7%). TNFα rs1800629 wild-type GG genotype was found in 106/130 BS patients (81.5%); the heterozygous genotype (GA) was identified in 24/130 patients (18.5%). No statistically significant differences were found in genotypes frequencies when the patients were stratified for presence and absence of each clinical manifestation (p>0.05), while statistically significant differences were found when the patients were compared for therapy (anti-TNFα drugs) response. In detail, 73/130 patients (56.2%) were treated with anti-TNFα agents. We found 16/73 (21.9%) non-responders patients (NRP). In NRP group, we identified 9/16 patients (56.3%) with GG genotype and 7/16 (43.7%) with GA genotype, while 8/57 (14.0%) responder patients showed GA genotype and 49/57 responder patients (86.0%) showed GG genotype (p=0.0093; OR: 0.21, CI: 0.06-0.729).

Conclusion: Here we described a low frequency of TNFα rs1800629 SNP-containing allele and the lack of association between SNP and BS clinical hallmark, as previously reported in literature [1-4]. We also found higher percentage of GG genotype in case of therapy response than GA genotype. The SNP is a promoter polymorphism that could affect the auto-inflammatory response and the therapy responsiveness, as suggested by our preliminary data of pharmacogenomics. Analyses of a larger cohort of patients are need to confirm the study findings and to explain the SNP role as outcome predictor.

References:

Disclosure of Interests: Maria Carmela Padula: None declared, Pietro Lecce: None declared, Nancy Lascaro: None declared, Giassi Gaia Tamborento: None declared, Rossa Paola Radice: None declared, Antonina Rita Limongi: None declared, Teresa Carbone: None declared, Angela Padula: None declared, Giuseppe Martelli: None declared, Salvatore D'Angelo Consultant of: AbbVie, Biogen, BMS, Celgene, Eli Lilly, MSD, Novartis, and UCB, Speakers bureau: AbbVie, BMS, Celgene, Eli Lilly, Novartis, Pfizer, and Sanofi.

DOI: 10.1136/annrheumdis-2020-eular.4240

AB0018
Objectives: To verify the hypothesis about the role of SAA1 rs12218 T / C gene polymorphism in the aptitude to various clinical JIA phenotypes.

Methods: The study included 132 children, of whom 66 were diagnosed with JIA and 66 were healthy unrelated volunteers (the college students) as a control group, comparable by gender and age. The group of patients with JIA consisted of 44 girls and 22 boys, with an average age of 11.7 ± 4.2 years and an average disease duration of 4.8 ± 3.8 years. The diagnosis and classification of JIA was established according to ILAR-2004 criteria. The JIA group included 30 (45%) patients with oligoarthritis (sJIA), of which 20 patients (67%) were positive for the HLA-B27 antigen (JIA-B27 +) and 10 (33%) patients with anterior uveitis (uJIA); 20 (30%) patients were assigned to the group with the polyarticular variant (pJIA), while all of them were seronegative for the rheumatoid factor; 16 (24%) patients were diagnosed with JIA with a systemic onset (sJIA). The frequencies of the T / C polymorphism of the SAA1 gene were assessed using an allele-specific polymerase chain reaction in a real time mode (RT-PCR).

Results: In the group of patients diagnosed with sJIA and (JIA-B27 +), the frequency of the C allele was significantly higher compared to the control (53.3% and 57.5% versus 37.1%, p = 0.035 and 0.022, respectively). No significant differences were detected in the frequencies of the mutant C allele between sJIA and pJIA and the control group. The logistics analysis of the frequency distribution of the alleles of the SAA1 gene demonstrated an increased risk of the C allele in formation of an aptitude to the sJIA variant (OR 1.94, 95% CI 1.00-3.76, p = 0.05). In the pJIA group, the frequency of the C allele was also increased compared to the control (OR 2.29, 95% CI 1.05-5.04, p = 0.022).

Conclusion: The data obtained confirm for the first time the involvement of the rs12218 polymorphism of the SAA1 gene in an aptitude to the oligoarthritis JIA clinical phenotype. The presented results require further replication researches using an enlarged number of patients from different population groups.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4119

AB0020

CORRELATION BETWEEN SERUM AND SYNOVIAL CONCENTRATION OF IL-17A AND MIRNA EXPRESSION IN RHEUMATOID ARTHRITIS PATIENTS

R. Shumaliieva1, D. Kachakova2, T. Velikova2, R. Kanova2, Z. Kolarov2, S. Monov1, 1Medical University – Sofia, Bulgaria, Department of Internal Medicine, Clinic of Rheumatology, Sofia, Bulgaria; 2Medical University – Sofia, Department of Medical Chemistry and Biochemistry, Molecular Medicine Center, Sofia, Bulgaria; 3Clinical Immunology, University Hospital Lozenetz, Sofia, Bulgaria

Background: Interleukin 17 (IL-17) is a proinflammatory cytokine, which overproduction promotes the autoimmune reaction in rheumatoid arthritis (RA). Posttranscriptional regulation of IL-17 by specific microRNAs (miRNAs) is of great interest in the recent years. 146a was associated with IL-17 expression in IL-17 producing cells, but the role of miRNA-146a in RA SF was not studied. The aim of this study was to examine a possible correlation between systemic and local concentrations of IL-17A and mir-223 expression in RA patients.

Methods: Expression levels of three miRNAs were determined in matched peripheral blood (PB) and synovial fluid (SF) samples of RA patients by relative quantitation method 2- ΔΔC(T). The control group consisted of 17 RA patients. Each miRNA was selected for analysis based on its expression level in PB and SF.

Results: miR-146a, miR-155 and miR-223 showed overexpression in RA SF compared to PB (p < 0.001). The ROC curve analysis showed diagnostic accuracy for miR-146a in SF with AUC=0.769, p=0.006, AUC for SF miR-155 was 0.858, p=0.001, and AUC for SF miR-223 was 0.841, p=0.001. The ROC curves for SF IL-17A showed area under the curve (AUC) = 0.885, p<0.001.

Conclusion: The difference between the systemic and local concentration of IL-17A and miRNAs expression shows that the inflammatory disease process leads to their altered expression with a possible role of these molecules in the disease pathogenesis. The higher local levels of miR-155, miR-146 and IL-17A confirm the data about the possible role of these miRNAs in regulating IL-17A production. The opposite changes of IL-17A and miR-223 systemic and local levels confirm the data about the possible role of miR-223 in regulating IL-17 function. Further analysis with larger sets is needed to confirm these results.

References:

Acknowledgments: The study was supported by Grant 14-D/2012, Grant 60/2013 and Grant 61/2015 from Medical University-Sofia, Bulgaria.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6226

AB0021

VARIABILITY OF THE RS333 IN LUPUS ERYTHEMATOSUS PATIENTS FROM THE POLISH POPULATION

K. Skonieczna1, D. Mlicka1, A. Wozniacka2, R. Czajkowski3, E. Robak2, M. Gawrych2, A. Dudek1, T. Grzybowski1, 1Department of Dermatology and Venereology, Bydgoszcz, Poland; 2Medical University – Lodz, Department of Dermatology and Venereology, Lodz, Poland; 3Collegium Medicum, Nicolaus Copernicus University, Department of Dermatology and Venereology, Bydgoszcz, Poland

Background: There are several subtypes of Lupus Erythematosus (LE), which may be limited to the skin (eg. Discoid Lupus Erythematosus, DLE) or involve multiple organ dysfunctions (Systemic Lupus Erythematosus, SLE). LE is an autoimmune disease that is influenced by genetic and environmental factors. Despite some genetic changes between DLE and SLE were previously shown, the complete genetic background of DLE is still unresolved [1]. Functional C-C chemokine receptor 5 (CCR5) receptor may have a protective effect on the development and progression of SLE [2, 3]. Thus it was important to investigate whether 32 bp deletion in rs333 is also associated with DLE development.

Objectives: The aim of this study was to investigate the variability of the CCR5 gene, within a polymorphic locus rs333 in SLE and DLE patients from the Polish population.

Methods: 120 LE patients (77 SLE patients and 43 DLE patients) and 100 healthy persons were recruited to the study from the Polish population. DNA was isolated from blood or buccal swabs. rs333 was genotyped by using polymerase chain reaction in a real time mode (RT-PCR).

Results: The CC genotype was associated with clinical symptoms of LE patients (p > 0.05). Moreover, the rs333 variability was not associated with clinical symptoms (p = 0.0375). Moreover, homozygotes without deletion in rs333 were found to have higher local levels of miR-223 in SF compared to serum (8.645 pg/ml versus 0.315 pg/ml, p=0.012). Levels of IL-17A were lower in RA SF compared to systemic levels. Levels of IL-17A were significantly less frequent within DLE patients group than in healthy individuals (p = 0.0375). Moreover, homozygotes without deletion in rs333 were found significantly more frequent in patients diagnosed with DLE than in healthy volunteers (p = 0.0214). In contrast, the differences in allele or genotype frequencies between SLE patients and healthy controls were not statistically significant (p > 0.05). Moreover, the rs333 variability was not associated with clinical symptoms of LE patients (p > 0.05).

Conclusion: Summarizing, the results obtained in this study suggest that the 32 bp deletion within rs333 could be a protective factor, that reduce the risk for DLE but not SLE development in the Polish population. However, due to the low statistical power of the obtained results, further studies on larger groups of patients and controls are needed to acquire more reliable data.

References: